Market research
OKYO OKYO Pharma Ltd ADR
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 8.3333
- Dividend yield
- Not available
- Beta
- 0.0
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GG00BMFG5F62
- Market cap
- 73M
- P/E ratio
- Not available
- Analyst target
- 8.3333
- Dividend yield
- Not available
- Beta
- 0.0
About
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the OKYO discussion.
No comments yet
Start a focused discussion about OKYO.